GB1218102A - Improvements in medicaments comprising drug/ion-exchange resin compounds - Google Patents

Improvements in medicaments comprising drug/ion-exchange resin compounds

Info

Publication number
GB1218102A
GB1218102A GB02704/68A GB1270468A GB1218102A GB 1218102 A GB1218102 A GB 1218102A GB 02704/68 A GB02704/68 A GB 02704/68A GB 1270468 A GB1270468 A GB 1270468A GB 1218102 A GB1218102 A GB 1218102A
Authority
GB
United Kingdom
Prior art keywords
drug
exchange resin
adsorbates
medicaments
ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB02704/68A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Philips Gloeilampenfabrieken NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philips Gloeilampenfabrieken NV filed Critical Philips Gloeilampenfabrieken NV
Priority to GB02704/68A priority Critical patent/GB1218102A/en
Priority to DE19691908946 priority patent/DE1908946A1/en
Priority to NL6903782A priority patent/NL6903782A/xx
Priority to FR6907111A priority patent/FR2004105A1/en
Priority to BE729827D priority patent/BE729827A/xx
Publication of GB1218102A publication Critical patent/GB1218102A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1,218,102. Cation exchange resin/drug adsorbates. C. A. CLARK (Philips' Gloeilampenfabrieken N.V.). 15 March, 1968, No. 12704/68. Heading C3P. [Also in Division A5] Resin-drug adsorbates are prepared by slurrying the resin with an aqueous solution of the drug, e.g. a therapeutically active amine. Examples relate to the preparation of " Zeo- Karb 225 SRC9" (Trade Mark)-isoxsuprine HCl and "Zeo-Karb SRC5 "-mebeverine adsorbates both resins being sulphonated polystyrenes cross-linked with divinyl benzene.
GB02704/68A 1968-03-15 1968-03-15 Improvements in medicaments comprising drug/ion-exchange resin compounds Expired GB1218102A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB02704/68A GB1218102A (en) 1968-03-15 1968-03-15 Improvements in medicaments comprising drug/ion-exchange resin compounds
DE19691908946 DE1908946A1 (en) 1968-03-15 1969-02-22 Pharmaceutical preparations and processes for making the same
NL6903782A NL6903782A (en) 1968-03-15 1969-03-11
FR6907111A FR2004105A1 (en) 1968-03-15 1969-03-13 PHARMACEUTICAL PREPARATIONS
BE729827D BE729827A (en) 1968-03-15 1969-03-13

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB02704/68A GB1218102A (en) 1968-03-15 1968-03-15 Improvements in medicaments comprising drug/ion-exchange resin compounds

Publications (1)

Publication Number Publication Date
GB1218102A true GB1218102A (en) 1971-01-06

Family

ID=10009580

Family Applications (1)

Application Number Title Priority Date Filing Date
GB02704/68A Expired GB1218102A (en) 1968-03-15 1968-03-15 Improvements in medicaments comprising drug/ion-exchange resin compounds

Country Status (5)

Country Link
BE (1) BE729827A (en)
DE (1) DE1908946A1 (en)
FR (1) FR2004105A1 (en)
GB (1) GB1218102A (en)
NL (1) NL6903782A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3317280A1 (en) * 1982-06-18 1983-12-22 Medical Research (Marketing) Pty. Ltd., North Ryde, New South Wales Composition and its use for the treatment of navicular disease of horses
US4459278A (en) * 1983-03-07 1984-07-10 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
GB2184731A (en) * 1985-11-08 1987-07-01 Covex Sa Preparation of (-)Eburnamenin-14-(15H)-one-resinates
US4859461A (en) * 1986-07-30 1989-08-22 Fisons Corporation Coatable ion exchange resins
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
US5032393A (en) * 1988-05-11 1991-07-16 Glaxo Group Limited Drug adsorbates
US5186930A (en) * 1988-11-14 1993-02-16 Schering Corporation Sustained release oral suspensions
WO1993007860A1 (en) 1991-10-24 1993-04-29 Kabi Pharmacia Ab New drug formulations with ion-exchangers
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
US6277366B1 (en) 1997-11-10 2001-08-21 Hisamitsu Pharmaceutical Co., Inc. Release-sustaining agent for drugs and sustained-release pharmaceutical composition

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1086226A (en) * 1976-11-26 1980-09-23 Yegnaswami Raghunathan Ion exchange resin prolonged release pharmaceutical preparations
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
EP0022117A3 (en) * 1979-06-08 1981-11-11 Ady Trenker Metoclopramid resinate and medicament containing it
US4762709A (en) * 1983-09-16 1988-08-09 Pennwalt Corporation Liquid prolonged release pharmaceutical formulations containing ionic constituents
PT93637A (en) * 1989-04-20 1990-11-20 Procter & Gamble METHOD FOR THE TREATMENT OF INTESTINAL / COLONIC FUNCTIONAL DISORDERS, ESPECIALLY THE INTESTINAL IRRITATION SYNDROME
IT1241417B (en) 1990-03-06 1994-01-14 Vectorpharma Int THERAPEUTIC COMPOSITIONS WITH CONTROLLED RELEASE OF DRUGS SUPPORTED ON CROSS-LINKED POLYMERS AND COATED WITH POLYMER FILM, AND THEIR PREPARATION PROCESS
JP3278192B2 (en) * 1992-04-03 2002-04-30 ロート製薬株式会社 Sustained release liquid
CA2645855C (en) 2006-03-16 2015-02-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
WO2008042218A1 (en) 2006-10-03 2008-04-10 Tris Pharma, Inc. Formulations containing an ionic mineral-ion exchange resin complex and uses thereof
BR112015003120B1 (en) 2012-08-15 2022-08-09 Tris Pharma , Inc METHYLPHENIDATE EXTENDED RELEASE CHEW TABLET AND ITS USE
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3317280A1 (en) * 1982-06-18 1983-12-22 Medical Research (Marketing) Pty. Ltd., North Ryde, New South Wales Composition and its use for the treatment of navicular disease of horses
US4459278A (en) * 1983-03-07 1984-07-10 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
GB2184731A (en) * 1985-11-08 1987-07-01 Covex Sa Preparation of (-)Eburnamenin-14-(15H)-one-resinates
GB2184731B (en) * 1985-11-08 1990-06-13 Covex Sa A process for the preparation of (-)eburnamenin-14-(15h)-one resinates
US4859461A (en) * 1986-07-30 1989-08-22 Fisons Corporation Coatable ion exchange resins
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
US5032393A (en) * 1988-05-11 1991-07-16 Glaxo Group Limited Drug adsorbates
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
US5186930A (en) * 1988-11-14 1993-02-16 Schering Corporation Sustained release oral suspensions
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
WO1993007860A1 (en) 1991-10-24 1993-04-29 Kabi Pharmacia Ab New drug formulations with ion-exchangers
US5643560A (en) * 1991-10-24 1997-07-01 Pharmacia & Upjohn Ab Drug formulation with ion-exchangers
US6277366B1 (en) 1997-11-10 2001-08-21 Hisamitsu Pharmaceutical Co., Inc. Release-sustaining agent for drugs and sustained-release pharmaceutical composition

Also Published As

Publication number Publication date
NL6903782A (en) 1969-09-22
DE1908946A1 (en) 1969-10-16
FR2004105A1 (en) 1969-11-21
BE729827A (en) 1969-09-15

Similar Documents

Publication Publication Date Title
GB1218102A (en) Improvements in medicaments comprising drug/ion-exchange resin compounds
BE695645A (en) PROCESS FOR THE PREPARATION OF MACROPOROUS RESINS, AND APPLICATIONS OF THESE TO OBTAINING ION EXCHANGERS.
GB857193A (en) Resin-drug compounds
GB1506664A (en) Antiviral compositions
GB857194A (en) Therapeutic agents comprising ion-exchange resins
GB982150A (en) Therapeutic resin complexes
ES8203349A1 (en) 1,2-Bis(nicotinamido)propane, process for preparing the same and pharmaceutical composition containing the same.
GB1237352A (en) Substituted propylamines
GB1224768A (en) Purification of antibiotic 833a
GB1195294A (en) Improvements in or relating to Pharmaceutical Compositions
NO881047L (en) ANTI-HYPERCOLESTEROLEMY GEL PREPARATION CONTAINING A PHARMACEUTICAL ACCEPTABLE, UNDERGRADABLE ANION EXCHANGE RESIN.
ES312173A1 (en) Procedure to prepare cosmetic formulations that have depigmenting activity. (Machine-translation by Google Translate, not legally binding)
GB1138968A (en) Improvements in or relating to indole derivatives
GB1253818A (en) Novel amines with pharmaceutical applications
DE3064539D1 (en) Acid-type ion exchange resins, their preparation, their use as medicines and compositions containing them
GB1402085A (en) 15-hydroxy vincamine
FR2329260A1 (en) Licking block for administering curative doses of medicaments - esp. anthelmintics, contains organoleptic agents such as sodium chloride and mineral salts
GB838952A (en) Resin-drug compounds
Toshioka Studies on the Bactericidal Activities of Rabbit Serum Report 2. The Influence of Starvation
AU114166A (en) Stable aqueous. solutions'of strength resins
GB1140655A (en) Pyrazine derivatives
Wachunas Boundaries, nine days ahead: investigations of a third entity
CA804582A (en) PHARMACEUTICAL PREPARATIONS CONTAINING .alpha.-AMINO-.beta.-(3:4-DICHLOROPHENYL)-BUTYRIC ACID, OR ITS SALTS
GB1145637A (en) New sympathomimetic amine
GB1256735A (en)